Founded in 2018, Wise Healthcare is a leading big data service platform in oncology. The platform provides clinical research services based on the real-world framework for pharmaceutical and medical device companies. It also enables medical institutions and patients with leading innovative diagnosis and treatment solutions.
Wise Healthcare (Chinese: 明智医疗) recently announced the completion of a Series A financing round of tens of millions of USD. This round of funding was jointly backed by Sinopharm CICC Medical Industry Innovation Investment Fund and CAC Holdings.
The proceeds will be mainly used to develop its tumor database service platform and the R&D of the digital medical pipeline.
Wise Healthcare focuses on the development of oncology-specific diseases databases. Since its establishment, the company has cooperated with the Chinese Society of Clinical Oncology (CSCO) to initiate the non-profit real-world research project: China Liver Cancer Clinical Survey (CLCS). Dedicated to building the world's largest liver cancer-specific disease database, the company covers more than 5,000 core experts, and more than 250,000 tumor diagnosis, treatment, and prognosis sample data.
In addition, the company has simultaneously deployed professional databases for various cancer types such as cholangiocarcinoma, pancreatic cancer, and gastric cancer. With deep advancement of data empowerment, Wise Healthcare has developed AI-based digital therapeutics which are software-driven, evidence-based interventions to prevent, manage and treat diseases.
Zhu Hong, the founder of Wise Healthcare, has many years of industry experience and rich resources in the medical data sector with a background in bioinformatics. He is committed to ensuring the academic research and promotion of healthcare providers through the establishment of a Chinese tumor patient-specific information database.
Regarding this round of financing, Mr. Zhu Hong claimed, "Wise Healthcare will build an R&D and service team that strives to become the industry benchmark in the tumor-specific disease databases. We will accelerate AI clinical solutions based on medical data and make more contributions to the health management of patients throughout the course of the disease.”
Wise Healthcare’s competitors include Medbanks (Chinese:思派科技), Xinyu Tech(Chinese: 新屿科技), and Linkdoc (Chinese: 零氪科技).